Skip to primary sidebar Search this website Home Company Products News & Releases Careers Contact Us COMPLIANCE US Compliance Statements Declaration of Compliance To request a summary of the Veloxis Comprehensive Compliance Program, please call +1 919 591 3090. Primary Sidebar COMPANY Overview Management Team Compliance NEWS & RELEASES Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor Sep 8, 2021 OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market Apr 26, 2021 Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program Jun 18, 2020 READ MORE ©2021 All rights reserved. Veloxis Pharmaceuticals, Inc. US-UNB-2100005 7/21 Info@veloxis.com | 1-844-VELOXIS (835-6947), Monday-Friday, 9AM-7PM ET Sitemap | Contact | Privacy Policy | Disclaimer We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT